Bayer AG is facing a fourth U.S. jury trial over allegations that its Roundup weed killer causes cancer, with four cancer patients in the hometown of its agricultural subsidiary Monsanto scheduled to begin making their case on Friday.
The lawsuit marks the first multi-plaintiff trial in the litigation over whether glyphosate, Roundup's active ingredient, is carcinogenic, and is the first trial outside of California.
Three consecutive juries found the company liable for causing cancer with damages of tens of millions of dollars awarded to each plaintiff.
Bayer is appealing those verdicts.
The company's share price has tumbled since the first verdict in August 2018 but the stock rose three per cent on Friday after Bloomberg reported a possible out-of-court settlement with some plaintiffs that could lead to a total payout of about $10 billion.